Local response to hypofractionated radiotherapy combined with systemic therapy predicts survival in advanced breast cancer: a retrospective cohort study
Year: 2026
Type: article
Study design: Observational Study
Abstract: Purpose The role of hypofractionated radiotherapy (HFRT) in advanced breast cancer beyond symptom palliation remains underexplored. This study evaluated the efficacy, safety, and prognostic factors of local HFRT combined with systemic therapy, with exploratory tissue-based genomic profiling. Methods This retrospective cohort included 67 advanced breast cancer patients who received HFRT (≥ 5 Gy/fraction, ≤ 10 fractions) to metastatic lesions between 2021 and 2026. Objective response rate (ORR), progression-free survival (PFS), time to next systemic therapy (TTNT), overall survival (OS), and adverse events (AEs) were assessed. Subgroup analyses were performed, and tumor sequencing was performed in 19 patients for somatic mutation analysis. Results The local ORR was 62.7%, with median local PFS of 8.0 months, overall PFS of 6.2 months, TTNT of 6.6 months, and OS of 19.1 months. Local response was independently associated with improved PFS (HR 0.31, 95%CI 0.16–0.59, P < 0.001) and OS (HR 0.29, 95%CI 0.15–0.58, P = 0.001). Liver metastasis was associated with lower response and worse survival. Deeper tumor shrinkage (≥ 50%) among responders was not significantly associated with additional survival benefits. AEs were manageable, with no grade 4–5 events. Common somatic mutations included TP53 (63.2%), PIK3CA (42.1%), and PTEN (36.8%), with no significant associations identified between individual gene mutations and ORR. Conclusion Local HFRT combined with systemic therapy showed favorable efficacy and safety in advanced breast cancer, with local response identified as a strong factor associated with survival benefit. However, no significant association was observed between deeper tumor shrinkage and additional survival benefits.
Institutions: Nanjing Drum Tower Hospital, Nanjing University
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $4,390
OpenAlex ID: W7233370671
